Fig. 1: MTHFD2 is overexpressed in MM and associated with poor prognosis.
A The MTHFD2 expression data from GSE6477 were analyzed in healthy donors (HD, n = 15) and newly diagnosed MM (NDMM, n = 69). B The MTHFD2 expression data of MM patients with different ISS stage from MMRF-CoMMpass dataset, ISS I stage (n = 281), ISS II stage (n = 298), ISS III stage (n = 258). C In the MMRF-CoMMpass dataset, Kaplan–Meier curves showed that overall survival of the patients with MTHFD2 high expression (MTHFD2high, n = 428) and MTHFD2 low expression (MTHFD2low, n = 430). D Comparisons of MTHFD2 expression in GSE46816 were shown, including eight pairs of CD138-positive (CD138+) and CD138-negative (CD138-) MM cells. E Relative MTHFD2 expression between MACS-sorted CD138+ and CD138- BMMCs from MM patients was detected using qRT-PCR normalized to ACTIN. F QRT-PCR assay showed that relative MTHFD2 expression normalized to ACTIN in PBMCs from healthy donor 1(HD1), PBMCs from healthy donor 2 (HD2), and MM cell lines including NCI-H929, OPM2, U266, LP-1, MM.1S, RPMI 8266. G Western blot assay was used to detect the MTHFD2 and Actin protein level of PBMCs from healthy donor 1 (HD1),PBMCs from healthy donor 2 (HD2), and MM cell lines including NCI-H929, OPM2, U266, LP-1, MM.1S, RPMI 8266. The data are presented as mean ± SD. Student’s t test was used to compare the differences between two groups. (*P < 0.05, **P < 0.01, ****P < 0.0001).
